CJC-1295 + Ipamorelin Blend – 10MG

CJC-1295 + Ipamorelin Blend: Benefits & Overview

The CJC-1295 + Ipamorelin Blend combines the two most studied growth hormone axis peptides in a single 10 mg vial — 5 mg CJC-1295 (with DAC) and 5 mg Ipamorelin. This is the gold-standard GH peptide stack available in Canada: CJC-1295 amplifies GH synthesis and sustains baseline GH elevation via the GHRH receptor, while Ipamorelin drives selective pulsatile GH release via the ghrelin receptor (GHSR-1a) without raising cortisol or prolactin.

Together, they exploit two distinct, complementary GH-stimulating pathways simultaneously — producing synergistic GH pulses larger than either peptide achieves individually.

CJC-1295 + Ipamorelin Benefits & Uses

• Synergistic GH/IGF-1 axis stimulation research
• GHRH + GHRP dual-pathway GH pulse studies
• Lean body mass and muscle hypertrophy models
• Fat metabolism, lipolysis, and body composition research
• Sleep quality and slow-wave sleep architecture studies
• Recovery, repair, and anabolic biology models

How the CJC-1295 + Ipamorelin Blend Works

CJC-1295 (GHRH analog with DAC) binds the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and creating sustained, elevated baseline GH availability for days per administration. Ipamorelin (GHSR agonist) simultaneously suppresses somatostatin (the GH-inhibiting brake) and drives GH secretory granule exocytosis via calcium signalling — without the HPA axis stimulation of older GHRPs. The result is a larger, cleaner GH pulse than either peptide alone — an example of receptor-level synergy in GH secretagogue research.

CJC-1295 + Ipamorelin 10mg Vial Specifications

• Contents: CJC-1295 with DAC (5 mg) + Ipamorelin (5 mg) — 10 mg total
• Purity: ≥98% each component (third-party HPLC verified)
• Form: Lyophilized powder (co-lyophilized blend)
• Storage: −20 °C (long-term); 4 °C (short-term)
• Reconstitution: Bacteriostatic water

CJC-1295 + Ipamorelin Canada FAQs

Why combine CJC-1295 with Ipamorelin?

CJC-1295 and Ipamorelin act on completely different receptors (GHRHR vs GHSR-1a) to stimulate GH release through complementary pathways. CJC-1295 increases GH synthesis and baseline elevation; Ipamorelin drives pulsatile release and suppresses somatostatin. The combination produces synergistic GH pulses exceeding what either compound achieves alone.

Does CJC-1295 + Ipamorelin raise cortisol?

Ipamorelin is selected for this combination specifically because it does not raise cortisol, prolactin, or ACTH — unlike GHRP-2 or GHRP-6. CJC-1295 also has no HPA axis activity. The combination targets the GH/IGF-1 axis cleanly.

Is the CJC-1295 + Ipamorelin blend available in Canada?

Reconstitution & Dosing Guide

How to Reconstitute

Add 3.0 mL of bacteriostatic water to the vial. Inject the water slowly down the inside wall of the vial — do not inject directly onto the powder. Gently swirl until fully dissolved; do not shake. This yields approximately 3.33 mg/mL total blend. Store the reconstituted vial at 4 °C and use within 28 days.

Low Starting Dose

• Dose per injection: 100 mcg each peptide (200 mcg total) — 3 units (0.03 mL) on a U-100 insulin syringe
• Frequency: Once daily, subcutaneous injection (before bed or upon waking)
• Cycle length: 8–12 weeks

Start at the lowest effective dose and adjust based on individual response. Consult a qualified healthcare professional before use.